Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate

Affiliations

• 1 Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou 510095, China.
• 2 Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Science, Guangzhou Medical University, Guangzhou 511436, China.
• 3 The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Department of Biomedical Engineering, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, China.
• 4 State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
• 5 School of Biomedical Sciences, State Key Laboratory of Liver Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong 852, Hong Kong.
• 6 Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.
• 7 General, Visceral and Cancer Surgery, University Hospital of Cologne, Cologne 50923, Germany.
• 8 Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, China.
• 9 Department of Clinical Oncology, State Key Laboratory of Liver Research, University of Hong Kong 852, Hong Kong.
• 10 The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Department of Biomedical Engineering, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, China. liuming@gzhmu.edu.cn maobinxie@gzhmu.edu.cn.
• 11 Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou 510095, China. liuming@gzhmu.edu.cn maobinxie@gzhmu.edu.cn.